Providence Portland Medical Center has filed an IND application with the FDA to study Galectin Therapeutics‘ GR-MD-02 in combination with ipilimumab (Bristol-Myers Squibb‘s Yervoy) in a Phase IB study of patients with metastatic melanoma. GR-MD-02 is Galectin Therapeutics’ proprietary molecule that binds to and inhibits galectin proteins, predominantly galectin-3. The application was prompted by findings from a preclinical study led by tumor immunology expert William L. Redmon...